AMLOGENYX
Live / Applied — First extension granted (statement of use) (as of 03 Oct 2025)
What this means for you
Not registered yet, but its 11 Sept 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98745183
- Mark type
- Stylized text
- Filed
- 11 Sept 2024
- Published for opposition
- 06 May 2025
- Attorney of record
- John Paul Oleksiuk
Goods and services
- Class 001 — Chemicals: Chemical, biological, and biochemical preparations for use in gene delivery technology, namely, nucleic acids in the nature of coding and non-coding deoxyribonucleic acids, plasmids, vectors, promotors, enhancers and regulatory sequences, for scientific purposes for use in vitro laboratory use; chemical, biological, and biochemical preparations for use in the manufacture of pharmaceutical preparations
- Class 005 — Pharmaceuticals: Chemical, biological, and biochemical preparations for use in gene delivery technology, namely, nucleic acids in the nature of coding and non-coding deoxyribonucleic acids, plasmids, vectors, promotors, enhancers and regulatory sequences, for medical purposes for use in vitro laboratory use
Owner
- Amlogenyx Inc., Novato, CA, US
- Amlogenyx Inc., Novato, CA, US
Prosecution history
- 04 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 03 Oct 2025 — SOU EXTENSION 1 GRANTED
- 03 Oct 2025 — SOU EXTENSION 1 FILED
- 03 Oct 2025 — SOU TEAS EXTENSION RECEIVED
- 01 Jul 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 06 May 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 06 May 2025 — PUBLISHED FOR OPPOSITION
- 30 Apr 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 03 Apr 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 28 Mar 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 28 Mar 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 28 Mar 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 14 Mar 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 14 Mar 2025 — NON-FINAL ACTION E-MAILED
- 14 Mar 2025 — NON-FINAL ACTION WRITTEN